Valuation: Roche Holding AG

Capitalization 26TCr 33TCr 28TCr 25TCr 45TCr 31,43500Cr 46TCr 3,09300Cr 1,19700Cr 14,92300Cr 1,23000Cr 1,20300Cr 51,99000Cr P/E ratio 2026 *
17.1x
P/E ratio 2027 * 15.9x
Enterprise value 27TCr 34TCr 29TCr 26TCr 47TCr 32,69300Cr 48TCr 3,21700Cr 1,24500Cr 15,52000Cr 1,27900Cr 1,25100Cr 54,07000Cr EV / Sales 2026 *
4.28x
EV / Sales 2027 * 4x
Free-Float
88.75%
Yield 2026 *
3.11%
Yield 2027 * 3.18%
1 day+0.88%
Current month+0.16%
3 months-12.59%
6 months+5.25%
Current year-1.65%
Current year 315.6
Extreme 315.6
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Operating Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 68 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5d. change 1-year change 3-years change Capi.($)
+0.88%+2.38% - - 33TCr
-0.00%+5.95%+32.68%+129.71% 90TCr
-1.77%+2.44%+49.81%+42.59% 55TCr
-0.18%+4.39%+14.33%+46.77% 37TCr
-0.10%+2.93%+27.56%+28.14% 28TCr
-0.79%+2.16%+31.97%+14.32% 28TCr
-1.79%0.00%+46.44%-2.95% 28TCr
+0.91%+3.07%-29.86%-47.97% 21TCr
-2.22%-1.62%+19.79%+45.01% 18TCr
-1.88%-1.33%+26.42%+64.42% 16TCr
Average -0.69%+1.89%+24.35%+35.56% 35.52TCr
Weighted average by Cap. -0.57%+3.03%+29.08%+55.20%

Financials

2026 *2027 *
Net sales 6.27TCr 7.97TCr 6.86TCr 5.98TCr 11TCr 7,64700Cr 11TCr 75TCr 29TCr 3,63000Cr 30TCr 29TCr 12,64800Cr 6.53TCr 8.3TCr 7.14TCr 6.23TCr 11TCr 7,96200Cr 12TCr 78TCr 30TCr 3,77900Cr 31TCr 30TCr 13,16700Cr
Net income 1.53TCr 1.95TCr 1.68TCr 1.46TCr 2.68TCr 1,86900Cr 2.73TCr 18TCr 7.12TCr 89TCr 7.31TCr 7.15TCr 3,09100Cr 1.64TCr 2.08TCr 1.79TCr 1.56TCr 2.87TCr 1,99800Cr 2.91TCr 20TCr 7.61TCr 95TCr 7.82TCr 7.65TCr 3,30400Cr
Net Debt 1.03TCr 1.31TCr 1.13TCr 983.98Cr 1.8TCr 1,25800Cr 1.83TCr 12TCr 4.79TCr 60TCr 4.92TCr 4.81TCr 2,08000Cr 343.79Cr 436.97Cr 376.01Cr 328.01Cr 601.34Cr 42TCr 611.27Cr 4.12TCr 1.6TCr 20TCr 1.64TCr 1.6TCr 69TCr
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
1,03,249
Date Price Change Volume
15/26/15 322.80 CHF +0.88% 10,70,366
13/26/13 320.00 CHF -0.47% 6,11,255
12/26/12 321.50 CHF +0.66% 6,54,692
11/26/11 319.40 CHF +1.30% 7,24,136
08/26/08 315.30 CHF -0.94% 5,90,249
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
322.80CHF
Average target price
360.76CHF
Spread / Average Target
+11.76%

Quarterly revenue - Rate of surprise